GLP-1 plateau: why weight loss stalls and what actually moves it

Weight loss on any method slows as it goes, for two reasons the drug does not override. The first is arithmetic: a lighter body needs fewer calories, so the same intake that produced a deficit at 100 kg produces a smaller one at 85 kg. Resting expenditure also falls somewhat more than the loss of mass alone predicts, an effect called adaptive thermogenesis that is well documented after large losses. The deficit shrinks even if nothing about eating changes.

The second is appetite. Weight loss lowers leptin and raises ghrelin, and those signals push hunger up as weight comes down. A GLP-1 drug suppresses appetite from a baseline that is rising, so the net effect weakens over time at a constant dose. People describe this as the drug wearing off. It is more accurate to say the body has caught up to it. The result is a point where intake and expenditure match again, and weight holds.

None of this means the drug has stopped working. The STEP 1 extension and SURMOUNT-4 both showed what happens when it is removed at the plateau: the weight comes back. The drug at the plateau is holding a new equilibrium, which is a different job from creating a deficit. Stopping semaglutide or tirzepatide covers that side.

The weight curves from the big trials share a shape. Loss is fastest in the first few months after titration finishes, continues at a slowing rate through the first year, and flattens in the back part of the trial. In STEP 1, semaglutide 2.4 mg produced about 15 percent average loss over 68 weeks, with most of it in place by around week 60. In SURMOUNT-1, tirzepatide reached about 15, 19.5 and 20.9 percent at 5, 10 and 15 mg over 72 weeks, and the curves were close to flat by the end at every dose.

That is why both compound pages describe the plateau as arriving around 12 to 18 months. The averages hide a wide spread: some people plateau early at 8 percent, others are still losing at 72 weeks. Retatrutide's phase 2 curve was still falling at 48 weeks, and the 80 week TRIUMPH-1 topline of about 28 percent suggests a longer runway before the plateau, though those are sponsor reported figures pending full publication.

The practical point is that a stall at month 10 on a stable dose is the trial curve doing what it did for thousands of participants. A stall at month 3 on a titration step is different: usually a dose that has reached its limit before the schedule did.

The labels are ladders, and a plateau means something different on each rung. Semaglutide runs 0.25, 0.5, 1.0, 1.7 and 2.4 mg weekly, each step held at least 4 weeks. Tirzepatide runs 2.5 mg for 4 weeks, then 5, 7.5, 10, 12.5 and 15 mg, with maintenance doses of 5, 10 or 15 mg studied. Many people stop climbing at the first step that controls appetite, which the labels allow, and plateau there months later.

The most common plateau in the semaglutide searches is at 1 mg, the top Ozempic diabetes dose, because many people using it off label never go higher. The STEP trials used 2.4 mg, and weight loss at 1 mg in the diabetes program was real but smaller. For tirzepatide the common hold is 5 or 7.5 mg, where SURMOUNT-1 showed about 15 percent, with 10 and 15 mg adding roughly 4 and 6 points on average. The semaglutide dosage chart and tirzepatide dosage chart lay out each rung.

Knowing where you are matters because the single intervention with trial evidence for moving a plateau is the next rung, and it only exists if there is a rung left.

Dose escalation within the label is the one lever with randomized data behind it. The SURMOUNT-1 dose response, about 15 percent at 5 mg and about 21 percent at 15 mg, means that for someone plateaued at a lower step, going up produces more loss on average. The label frames every increase as conditional on tolerance and spaces them at least 4 weeks apart, and the side effects article covers what each step brings. Above the top step there is no lever.

Resistance training and protein have strong evidence for body composition and modest evidence for the number on the scale. Reviews estimate 30 to 40 percent of weight lost on these drugs can be lean mass, and the STEP 1 DEXA substudy put it near 39 percent. Lifting two or three times a week and protein in the 1.2 to 1.6 grams per kilogram range preserve the muscle that sets resting expenditure, which slows the fall in calorie needs behind the plateau. Muscle loss on GLP-1 drugs covers both.

Sleep is the third, with observational and some experimental support: short sleep raises ghrelin, lowers leptin and increases intake the next day. Fixing it is not a weight loss method, but losing it is a reliable way to stall. Beyond these the honest list is short. Tracking intake for two weeks often shows that calories have drifted up as appetite adapted, which is the plateau's mechanism made visible, and that is worth doing before changing anything pharmacological.

The forum answer to a plateau is to change compounds, and the grey market makes that easy. Switching from semaglutide to tirzepatide has head to head support in general, since SURMOUNT-5 showed about 20 versus 14 percent at 72 weeks, but no trial has tested switching after a plateau, and a switch means a new titration with new side effects. Switching to retatrutide means moving to an unapproved investigational drug with a heart rate signal and unverified vials. That is a drug change with its own risks, not a plateau strategy. The three way comparison covers what is known about each.

Adding a second compound is the other sales pitch. Cagrilintide is the one with a real mechanism, since amylin satiety adds to GLP-1 satiety, and CagriSema reached about 20 percent in phase 3. But the only combination data started both drugs together; nobody has trialed adding cagrilintide to someone already plateaued on semaglutide, and the compound page rates that use as emerging. The cagrilintide and semaglutide stack page is clear about the gap.

Further down the list are compounds sold as fat burners or metabolic boosters: MOTS-c, AOD-9604, 5-amino-1MQ, and the growth hormone secretagogues sold as muscle protectors. None has a human trial showing additional weight loss on top of a GLP-1 drug, and the tirzepatide and ipamorelin stack page says the same for lean mass. Buying them to break a plateau is buying a hypothesis.

At some point the plateau is the result. The trials ended with participants holding a weight 15 to 20 percent below where they started, appetite controlled, blood pressure and glucose improved, and that is what the drugs were approved to do. Someone a year in at the top label step, down 18 percent, with a stable weight and manageable side effects, has not stalled. They have arrived, and the question becomes how to hold it, which the compound pages and the microdosing article address from different angles.

The distinction matters because the two situations call for opposite moves. A stall at a low rung with food noise returning has a trial supported next step. A stable weight at the top rung with quiet appetite has none, and chasing more loss there usually means the grey market. A lower number is also not automatically better if the extra loss is disproportionately lean mass.

If the goal weight has not been reached and the ladder is exhausted, that is a conversation for a clinician, who can weigh the options the trials did test. It is not a problem a vendor can solve.